Drug intelligence / Profile preview

VIR-2020

Development stage: Unknown
Lead developer: Vir Biotechnology
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics

Overview

VIR-2020 is a vaccine candidate developed by Vir Biotechnology for the prevention of tuberculosis (TB). It utilizes a cytomegalovirus (CMV) vector-based platform, which was acquired through the purchase of TomegaVax and licensed from Oregon Health & Science University (OHSU). This platform is designed to elicit a robust and sustained T cell response against *Mycobacterium tuberculosis*. The program has received significant funding from the Bill & Melinda Gates Foundation to support manufacturing and early clinical development.

Beyond the preview

Go deeper on VIR-2020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIR-2020.

Explore the full profile